PDF icon PDF herunterladen
Open Access
CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2018; 76(08): 522-526
DOI: 10.1590/0004-282X20180076
Article

Blepharospasm with elevated anti-acetylcholine receptor antibody titer

Blefaroespasmo com título elevado de anticorpos antirreceptores de acetilcolina
Min Tang
1   Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China
,
Wu Li
2   Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, Province, P.R. China
,
Ping Liu
1   Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China
,
Fangping He
1   Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China
,
Fang Ji
1   Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China
,
Fanxia Meng
1   Department of Neurology, First Affiliated Hospital, Zhejiang University School of Medicine, 79 Qingchun Road, Hangzhou 310003, China
› Institutsangaben
› Weitere Informationen
Auch verfügbar aufeRef
  Lizenzen und Reprints
Preview

ABSTRACT

Objective: To determine whether serum levels of anti-acetylcholine receptor antibody (anti-AChR-Abs) are related to clinical parameters of blepharospasm (BSP).

Methods: Eighty-three adults with BSP, 60 outpatients with hemifacial spasm (HFS) and 58 controls were recruited. Personal history, demographic factors, response to botulinum toxin type A (BoNT-A) and other neurological conditions were recorded. Anti-AChR-Abs levels were quantified using an enzyme-linked immunosorbent assay.

Results: The anti-AChR Abs levels were 0.237 ± 0.022 optical density units in the BSP group, which was significantly different from the HFS group (0.160 ± 0.064) and control group (0.126 ± 0.038). The anti-AChR Abs level was correlated with age and the duration of response to the BoNT-A injection.

Conclusion: Patients with BSP had an elevated anti-AChR Abs titer, which suggests that dysimmunity plays a role in the onset of BSP. An increased anti-AChR Abs titer may be a predictor for poor response to BoNT-A in BSP.

RESUMO

Objetivo: Determinar se os níveis séricos do anticorpo antirreceptor de acetilcolina (anti-AChR-Abs) estão relacionados aos parâmetros clínicos do blefaroespasmo (BSP).

Métodos: Fora recrutados 83 adultos com BSP, 60 pacientes ambulatoriais com espasmo hemifacial (HFS) e 58 controles. Foi aplicado um questionário para registrar história pessoal, fatores demográficos, resposta à toxina botulínica tipo A (BoNT-A) e outras condições neurológicas. Os níveis de anti-AChR-Abs foram quantificados usando um ensaio imunoenzimático.

Resultados: O nível de anti-AChR-Abs foi de 0,237 ± 0,022 unidades de densidade óptica (OD) no grupo BSP, significativamente diferente em comparação com o grupo HFS (0,160 ± 0,064) e o grupo controle (0,126 ± 0,038). O nível de anti-AChR-Abs se correlacionou com a idade e a duração da resposta à injeção de BoNT-A.

Conclusão: Pacientes com BSP apresentaram títulos elevados de anti-AChR-Abs, o que sugere que a desimunidade desempenha um papel no surgimento de BSP. O aumento do título de anti-AChR-Abs pode ser um preditor de resposta insuficiente à BoNT-A em BSP.

Keywords:

Blepharospasm - hemifacial spasm - botulinum toxin type A

Palavras-chave:

blefaroespasmo - espasmo hemifacial - toxina botulínica tipo A

Support

Natural Science Fund of Zhejiang Province [grant no. LQ14H090002] and the Traditional Chinese Medicine Science and Technology Plan of Zhejiang Province [grant no.2015ZQ023].




Publikationsverlauf

Eingereicht: 26. November 2017

Angenommen: 04. Mai 2018

Artikel online veröffentlicht:
23. August 2023

© 2023. Academia Brasileira de Neurologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Malinovsky V. Benign essential blepharospasm. J Am Optom Assoc. 1987 Aug;58(8):646-51
  • 2 Dalakas MC. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target. Pharmacol Ther. 2006 Oct;112(1):57-70. https://doi.org/10.1016/j.pharmthera.2006.03.005
  • 3 Zhou C, Wu J, Zhang H. Myasthenia gravis and Guillain-Barré cooccurrence syndrome. Am J Emerg Med. 2013 Dec;31(12):1710. https://doi.org/10.1016/j.ajem.2013.08.030
  • 4 Mehanna R, Patton EL Jr, Phan CL, Harati Y. Amyotrophic lateral sclerosis with positive anti-acetylcholine receptor antibodies. Case report and review of the literature. J Clin Neuromuscul Dis. 2012 Dec;14(2):82-5. https://doi.org/10.1097/CND.0b013e31824db163
  • 5 Nikolic A, Rakocevic Stojanovic V, Romac S, Savic D, Basta I, Lavrnic D. The coexistence of myasthenia gravis and myotonic dystrophy type 2 in a single patient. J Clin Neurol. 2013 Apr;9(2):130-2. https://doi.org/10.3988/jcn.2013.9.2.130
  • 6 Kurlan R, Jankovic J, Rubin A, Patten B, Griggs R, Shoulson I. Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue? Arch Neurol. 1987 Oct;44(10):1057-60. https://doi.org/10.1001/archneur.1987.00520220055017
  • 7 Fahn S. Concept and classification of dystonia. Adv Neurol. 1988;50:1-8.
  • 8 Jankovic J, Kenney C, Grafe S, Goertelmeyer R, Comes G. Relationship between various clinical outcome assessments in patients with blepharospasm. Mov Disord. 2009 Feb;24(3):407-13. https://doi.org/10.1002/mds.22368
  • 9 Yang H, Goluszko E, David C, Okita DK, Conti-Fine B, Chan TS et al. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J Clin Invest. 2002 Apr;109(8):1111-20. https://doi.org/10.1172/JCI14255
  • 10 Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC. Bradley's neurology in clinical practice. 6th ed. London: Elsevier; 2012. Bashar Katirji. Clinical Neurophysiology, Chapter 32B,:416-19.
  • 11 Leite MI, Waters P, Vincent A. Diagnostic use of autoantibodies in myasthenia gravis. Autoimmunity. 2010 Aug;43(5-6):371-9. https://doi.org/10.3109/08916930903541208
  • 12 Hara K, Matsuda A, Kitsukawa Y, Tanaka K, Nishizawa M, Tagawa A. Botulinum toxin treatment for blepharospasm associated with myasthenia gravis. Mov Disord. 2007 Jul;22(9):1363-4. https://doi.org/10.1002/mds.21558
  • 13 Kamada M, Fukutake T, Hiroyoshi Y, Sato S, Shibayama H, Nishino H. [A case of myasthenia gravis associated with blephaloptosis mimicking blephalospasm]. Rinsho Shinkeigaku. 2004 Jan;44(1):54. Japanese.
  • 14 Zee DS, Chu FC, Leigh RJ, Savino PJ, Schatz NJ, Reingold DB et al. Blink-saccade synkinesis. Neurology. 1983 Sep;33(9):1233-6. https://doi.org/10.1212/WNL.33.9.1233
  • 15 Hain TC, Zee DS, Mordes M. Blink-induced saccadic oscillations. Ann Neurol. 1986 Mar;19(3):299-301. https://doi.org/10.1002/ana.410190315
  • 16 Tan EK, Chan LL, Lim SH, Lim WE, Khoo JB, Tan KP. Role of magnetic resonance imaging and magnetic resonance angiography in patients with hemifacial spasm. Ann Acad Med Singapore. 1999 Mar;28(2):169-73.
  • 17 Moore CE, Lees AJ, Schady W. Multiple sclerosis leading to blepharospasm and dystonia in a sibling pair. J Neurol. 1996 Sep;243(9):667-70. https://doi.org/10.1007/BF00878668
  • 18 Kanzato N, Motomura M, Suehara M, Arimura K. Lambert-Eaton myasthenic syndrome with ophthalmoparesis and pseudoblepharospasm. Muscle Nerve. 1999 Dec;22(12):1727-30. https://doi.org/10.1002/(SICI)1097-4598(199912)22:12<1727::AID-MUS19>3.0.CO;2-K
  • 19 Jankovic J, Patten BM. Blepharospasm and autoimmune diseases. Mov Disord. 1987;2(3):159-63. https://doi.org/10.1002/mds.870020303
  • 20 Lange O, Bigalke H, Dengler R, Wegner F, Groot M, Wohlfarth K. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing? Clin Neuropharmacol. 2009 Jul-Aug;32(4):213-8. https://doi.org/10.1097/WNF.0b013e3181914d0a
  • 21 Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna). 2013 Feb;120(2):275-90. https://doi.org/10.1007/s00702-012-0893-9
  • 22 Rana AQ, Shah R. Combination of blepharospasm and apraxia of eyelid opening: a condition resistant to treatment. Acta Neurol Belg. 2012 Mar;112(1):95-6. https://doi.org/10.1007/s13760-012-0019-z
  • 23 Dolimbek BZ, Aoki KR, Steward LE, Jankovic J, Atassi MZ. Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A. Mol Immunol. 2007 Feb;44(5):1029-41. https://doi.org/10.1016/j.molimm.2006.03.011
  • 24 Atassi MZ, Dolimbek BZ, Jankovic J, Steward LE, Aoki KR. Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology. 2011 Jul;216(7):782-92. https://doi.org/10.1016/j.imbio.2010.12.009
  • 25 Rajagopalan N, Humphrey PR, Bucknall RC. Torticollis and blepharospasm in systemic lupus erythematosus. Mov Disord. 1989;4(4):345-8. https://doi.org/10.1002/mds.870040410
  • 26 Ishii W, Matsuda M, Hanyuda M, Momose M, Nakayama J, Ehara T et al. Comparison of the histological and immunohistochemical features of the thymus in young- and elderly-onset myasthenia gravis without thymoma. J Clin Neurosci. 2007 Feb;14(2):110-5. https://doi.org/10.1016/j.jocn.2005.11.048